Krystexxa Side Effects
Generic name: pegloticase
Note: This document contains side effect information about pegloticase. Some of the dosage forms listed on this page may not apply to the brand name Krystexxa.
Some side effects of Krystexxa may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to pegloticase: intravenous solution
Along with its needed effects, pegloticase (the active ingredient contained in Krystexxa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking pegloticase:More common
- Chest pain or discomfort
- difficult or labored breathing
- difficulty with swallowing
- facial swelling
- fast heartbeat
- fever or chills
- flushing or redness of the skin
- gout flare
- hives or welts
- nausea or vomiting
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- shortness of breath
- skin rash
- tightness in the chest
- unusual tiredness or weakness
- unusually warm skin
- Decreased urine output
- dilated neck veins
- extreme fatigue
- irregular breathing
- irregular heartbeat
- swelling of the face, fingers, feet, or lower legs
- troubled breathing
- weight gain
Some side effects of pegloticase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- difficulty having a bowel movement (stool)
- large, flat, blue, or purplish patches in the skin
- muscle aches
- sore throat
- stuffy or runny nose
For Healthcare Professionals
Applies to pegloticase: intravenous solution
Immunologic side effects have included anaphylaxis, which occurred at a frequency of 6.5% in patients treated with pegloticase (the active ingredient contained in Krystexxa) 8 mg every 2 weeks, compared to none with placebo. Infusion reactions occurred in 26% of patients in the 2 week dosing regimen group and 41 % of patients in the 4 week dosing regimen group compared to 5% of placebo-treated patients. Manifestations of these reactions included urticaria (10.6%), dyspnea (7.1%), chest discomfort (9.5%), chest pain (9.5%), erythema (9.5%), and pruritus (9.5%). These manifestations overlap with the symptoms of anaphylaxis, but in a given patient did not occur together to satisfy the clinical criteria for diagnosing anaphylaxis. Infusion reactions are thought to result from release of various mediators, such as cytokines. Infusion reactions occurred at any time during a course of treatment with approximately 3% occurring with the first infusion, and approximately 91% occurring during the time of infusion. Some infusion reaction manifestations were reduced with slowing the rate of infusion, or stopping the infusion and restarting the infusion at a slower rate. These infusion reactions occurred with all patients being pretreated with an oral antihistamine, intravenous corticosteroid and acetaminophen.
Local side effects have included infusion reactions (26%) compared to placebo (5%).
Metabolic side effects have included gout flares, which were more common during the first 3 months of treatment with pegloticase (the active ingredient contained in Krystexxa) compared with placebo. All patients in clinical trials were pretreated with an oral antihistamine, intravenous corticosteroid and/or acetaminophen to prevent anaphylaxis and infusion reaction. Patients also received nonsteroidal anti-inflammatory drugs or colchicine, or both, for at least 7 days as gout flare prophylaxis before beginning pegloticase treatment.
Two cases of congestive heart failure exacerbation occurred during clinical trials in patients receiving treatment with pegloticase (the active ingredient contained in Krystexxa) 8 mg every 2 weeks versus no cases in placebo treated patients. Four trial participants had exacerbations of preexisting congestive heart failure while receiving pegloticase 8 mg every 2 weeks during an open-label extension study. Other cardiovascular side effects have included chest pain (6%).
Gastrointestinal side effects have included nausea (12%), constipation (6%), and vomiting (5%).
Respiratory side effects have included nasopharyngitis (7%).
Dermatologic side effects have included contusion or ecchymosis (11%).
More Krystexxa resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.